MetaCap

Twist Bioscience Corporation (TWST)

NASDAQ: TWSTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

103.32-8.30 (-7.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TWST stock chart

Technical analysis

Key statistics

All statistics
Forward P/E
1,581.51
EPS (TTM)
-$2.08
52-week range
28.27 – 219.71
Day range
101.00 – 108.50
Volume / Avg
3.38M / 2.49M
Beta
—

52-week range

$28.27$219.71

TWST stock today

Shares of Twist Bioscience (TWST) finished lower on Nov 20 at $103.32, a drop of 7.44% or $8.30 per share, versus the S&P 500's 3.70% decline. At this level, TWST sits in the middle of its 52-week range of $28.27 to $219.71: 53.0% below the high, set on Oct 6, 2026 and 265.5% above the low. TWST is up 225.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 261.8%.

Twist Bioscience has posted a net loss over the last twelve months (EPS of -$2.08), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Twist Bioscience

Company profile

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Emily Marine Leproust Ph.D.
Headquarters
South San Francisco, CA
Employees
1,080
IPO year
2018

Financial highlights

Full financials

In fiscal 2026, Twist Bioscience generated $459.4 million in revenue, up 22.0% from fiscal 2025, its 9th consecutive year of revenue growth. Twist Bioscience reported a net loss of $130.2 million, compared with a loss of $77.7 million a year earlier. Gross margin was 52.4% (up from 50.7%) and operating margin -30.4%.

Twist Bioscience annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$459.43M$376.57M$312.97M$245.11M$203.56M
Growth+22.00%+20.32%+27.69%+20.41%+53.83%
Net income$-130.20M$-77.67M$-208.73M$-204.62M$-217.86M
EPS (diluted)$-2.08$-1.30$-3.60$-3.60$-4.04

Analyst forecast

Forecast

Consensus (14 analysts)

buy

Avg. price target

$128.82+24.68%

  • Strong buy 2
  • Buy 7
  • Hold 4
  • Sell 1
  • Strong sell 0

Target range

Low $45.00High $175.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.32 vs $-0.43
Surprise
+25.58%

TWST news

All TWST news

Twist Bioscience peers

Health Care sector
TWST peer companies
CompanyPrice% ChgMarket capCompare
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs TWST
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs TWST
IBRXImmunityBio Inc.6.02-8.37%$6.40Bvs TWST
KODKodiak Sciences Inc97.17-0.75%$6.35Bvs TWST
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs TWST
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs TWST
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs TWST
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs TWST

Indexes, lists and sector

Twist Bioscience stock FAQ

What is Twist Bioscience's stock price today?

TWST last traded at $103.32 as of Nov 20, 4:00 PM EST, down 7.44% on the day. Prices are delayed at least 15 minutes.

Who is Twist Bioscience's CEO?

Dr. Emily Marine Leproust Ph.D. is the chief executive officer of Twist Bioscience Corporation, which has about 1,080 employees.

What is the TWST 52-week high?

The 52-week high for TWST is $219.71 and the 52-week low is $28.27. The stock is currently 53.0% below its high.

Compare TWST